Royce & Associates LP reduced its stake in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 14.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,201,639 shares of the biotechnology company’s stock after selling 195,000 shares during the period. Royce & Associates LP’s holdings in Progenics Pharmaceuticals were worth $5,576,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in PGNX. BlackRock Inc. grew its holdings in shares of Progenics Pharmaceuticals by 1.8% during the fourth quarter. BlackRock Inc. now owns 13,530,763 shares of the biotechnology company’s stock worth $56,828,000 after purchasing an additional 237,520 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Progenics Pharmaceuticals by 16.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,046,431 shares of the biotechnology company’s stock valued at $31,641,000 after purchasing an additional 727,575 shares in the last quarter. Eagle Asset Management Inc. boosted its holdings in Progenics Pharmaceuticals by 0.3% in the 1st quarter. Eagle Asset Management Inc. now owns 4,508,430 shares of the biotechnology company’s stock valued at $20,919,000 after purchasing an additional 13,065 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in Progenics Pharmaceuticals by 19.2% in the 1st quarter. Rice Hall James & Associates LLC now owns 2,293,179 shares of the biotechnology company’s stock valued at $10,640,000 after purchasing an additional 369,680 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Progenics Pharmaceuticals by 9.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,160,542 shares of the biotechnology company’s stock valued at $7,277,000 after purchasing an additional 97,561 shares in the last quarter. Institutional investors and hedge funds own 80.97% of the company’s stock.

Shares of PGNX stock traded down $0.06 during midday trading on Monday, reaching $4.13. 18,133 shares of the company traded hands, compared to its average volume of 671,997. Progenics Pharmaceuticals, Inc. has a 1-year low of $3.62 and a 1-year high of $9.42. The company has a current ratio of 4.81, a quick ratio of 4.81 and a debt-to-equity ratio of 0.45. The company has a market cap of $355.06 million, a price-to-earnings ratio of -6.48 and a beta of 2.45.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative net margin of 436.57% and a negative return on equity of 61.96%. The company had revenue of $4.28 million during the quarter, compared to the consensus estimate of $3.71 million. Sell-side analysts forecast that Progenics Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Thursday, February 21st. BidaskClub raised Progenics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $9.19.

TRADEMARK VIOLATION NOTICE: “Royce & Associates LP Has $5.58 Million Stake in Progenics Pharmaceuticals, Inc. (PGNX)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/royce-associates-lp-has-5-58-million-stake-in-progenics-pharmaceuticals-inc-pgnx/3030338.html.

Progenics Pharmaceuticals Profile

Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Further Reading: Short Selling

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.